Sanofi & Cipla Join Hands To Promote CNS Product Portfolio in India

Pharmaceutical and healthcare firm Sanofi announced an exclusive distribution with Cipla for their Central Nervous System (CNS) product line in India. Because of this partnership, Cipla will deal with disseminating Sanofi India's six CNS brands, which incorporate the business driving Frisium® brand of anti-epileptic medications.

Cipla will utilize its abilities and solid, extensive organization of merchants, establishments, and market outreach projects to grow admittance to these medicines for patients who need them. At the same time, Sanofi India will keep owning, importing, and manufacturing its whole scope of CNS items across plants in India and abroad.

Rodolfo Hrosz, Managing Director, Sanofi India Limited, said “Sanofi India’s CNS products are leaders in their respective categories. These well-established brands already improve lives of many patients across urban centres in the country. Cipla’s wide presence will enable us to expand the reach of this portfolio to healthcare professionals and patients across all India.”

Mr. Achin Gupta, Chief Executive Officer – One India Business, Cipla Limited, said “Enhancing access to high quality treatments is central to our purpose of ‘Caring for Life’. We are pleased to collaborate with Sanofi India to enhance accessibility to highly efficacious and quality therapeutic solutions in CNS and bring value to patients across the country. Central Nervous System is one of the most challenging areas in medicine, and we believe this partnership is a significant step forward to address unmet needs of patients.”

Sanofi India focuses on speeding up major areas of strength for its pipeline into India across numerous therapeutic areas, including Diabetes, Transplants, Uncommon Illnesses, Consumer Healthcare and Vaccines.